Day: March 7, 2024

Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., March 07, 2024 (GLOBE NEWSWIRE) — Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the full year ended December 31, 2023 after the market close on Thursday, March 14, 2024. The Vaxart senior management team will host a conference call on the same day, beginning at 4:30 p.m. ET. The conference call can be accessed using the following information: Webcast: Click hereDate: Thursday, March 14, 2024 – 4:30 p.m. ETDomestic: (877) 407-0832International: (201) 689-8433Conference ID: 13744368 Investors may submit written questions in advance of the conference call to ir@vaxart.com. A replay of the webcast will be available on the Company’s website at www.vaxart.com following the conclusion of the event. About...

NEW HOPE, Pa., March 07, 2024 (GLOBE NEWSWIRE) — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that company management will present and be available for one-on-one meetings at multiple conferences throughout March 2024. Details on the presentations are shown below. Oppenheimer Annual Healthcare MedTech and Services ConferenceFormat: Corporate Presentation Date: March 12, 2024Time: 3:20 PM ETWebcast: https://wsw.com/webcast/oppenheimer34/obio/2767483 Barclays 26th Annual Global Healthcare ConferenceFormat: Fireside ChatDate: March 14, 2024Time: 11:15 AM ET A live audio webcast of the Oppenheimer presentation can be accessed through the Investors section of the Company’s...

GREENWICH, Conn., March 07, 2024 (GLOBE NEWSWIRE) — Oxford Lane Capital Corp. (NasdaqGS: OXLC) (NasdaqGS: OXLCM) (NasdaqGS: OXLCP) (NasdaqGS: OXLCL) (NasdaqGS: OXLCO) (NasdaqGS: OXLCZ) (NasdaqGS: OXLCN) (the “Company”) today announced the following net asset value (“NAV”) estimate as of February 29, 2024.Management’s unaudited estimate of the range of the NAV per share of our common stock as of February 29, 2024 is between $4.90 and $5.00. This estimate is not a comprehensive statement of our financial condition or results for the month ended February 29, 2024. This estimate did not undergo the Company’s typical quarter-end financial closing procedures and was not approved by the Company’s board of directors. We advise you that our NAV per share for the quarter ending March 31, 2024 may differ materially from this estimate, which...

Total Revenue of $37.0 million for the Fourth QuarterFull year Self-Service Revenue up 33% YoYQ4 illumin Self-Service Revenue up 75% QoQ and 271% YoY (All monetary figures are expressed in Canadian dollars unless otherwise stated) TORONTO, March 07, 2024 (GLOBE NEWSWIRE) — illumin Holdings Inc. (TSX: ILLM) (“illumin” or “Company”), a journey advertising technology company that empowers marketers to make smarter decisions about communicating with online consumers, today announced its financial results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter 2023 HighlightsFourth quarter 2023 revenue was $37.0 million, down 8% year-over-year, reflecting anticipated lower managed service revenue due to the Company’s ongoing strategic shift to focus on the self-service business and challenging market conditions...

Data support evaluation of the effects of two weeks of TNX-102 SL therapy on severity of acute stress reaction (ASR) and frequency of acute stress disorder (ASD) and PTSD after civilian motor vehicle collision in upcoming U.S. DoD-Funded Phase 2 investigator-initiated OASIS trial Nominal improvement in PTSD severity and measures of sleep quality at Week 4 in the HONOR study support development of bedtime TNX-102 SL therapy in the immediate aftermath of trauma TNX-102 SL (Tonmya™) is also in late-stage development for the management of fibromyalgia for which NDA preparation is ongoing CHATHAM, N.J., March 07, 2024 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced the publication...

SCOTTSDALE, Ariz., March 07, 2024 (GLOBE NEWSWIRE) — Adamas One Corp. (NASDAQ: JEWL), a leading innovator in lab-grown diamond technology, is proud to announce that it has been honored with the esteemed title of “Best Lab-Grown Manufacturer for 2023” by Manufacturing Technology Insights Magazine. This recognition highlights Adamas One Corp.’s relentless commitment to pioneering advancements in lab-grown diamonds, both within the jewelry industry and the technology sector. Manufacturing Technology Insights Magazine recognized Adamas One Corp. for its groundbreaking contributions to lab-grown diamond manufacturing, emphasizing the company’s focus on quality, sustainability, and social responsibility. As the lab-grown diamond industry continues to experience rapid growth, Adamas One Corp. remains at the forefront,...

DALLAS, March 07, 2024 (GLOBE NEWSWIRE) — Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced the formation of a wholly-owned subsidiary dedicated to advancing intellectual property (IP) relevant to the broader AI ecosystem, with a specific emphasis on healthcare. “After conducting a comprehensive review of our IP portfolio, we are confident that Spectral AI has effectively safeguarded its current and anticipated future product offerings through a combination of patents and trade secrets. During this review, we identified additional opportunities for the Company to enhance its position and add value for its shareholders by developing or acquiring IP applicable to the...

Agreement with a leading cancer treatment group to advance the clinical development of Bria-OTS+ (breast cancer) and Bria-PROS+ (prostate cancer), BriaCell’s novel off-the-shelf personalized cancer vaccines, marks a major milestone for BriaCellPHILADELPHIA and VANCOUVER, British Columbia, March 07, 2024 (GLOBE NEWSWIRE) —  BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces that it has received and executed a letter of intent with Paula Pohlmann, MD, MSc, PhD, Associate Professor, Department of Investigational Cancer Therapeutics and Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX to advance the clinical development...

HORSHAM, Pa., March 07, 2024 (GLOBE NEWSWIRE) — STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced an initiative aimed at expanding insurance coverage for essential treatments for conditions such as mycosis fungoides, lichen planus, alopecia areata, and cutaneous T-Cell lymphoma (CTCL), with an initial targeted focus on expanding coverage for vitiligo and atopic dermatitis, skin diseases effecting up to 3 and 16 million people in the United States respectively1. The Company is leveraging its extensive patient database and engaging in targeted governmental relations efforts, this initiative focuses on broadening Current Procedural Terminology (“CPT”)...